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Abstract 
In recent years, increased interest in the human health benefits of vitamin D has led to 
demand for improved analysis of patient vitamin D ‘status’. Studies to date have focused 
primarily on a single vitamin D metabolite, 25-hydroxyvitamin D, despite the existence of a 
broad range of vitamin D metabolites, referred to as the vitamin D metabolome. This study 
reports on the development of a rapid UPSFC-MS/MS method for the analysis of nine 
vitamin D metabolites in human serum. Optimum separation was obtained with a Lux-
Cellulose chiral column. We observed an orthogonal elution order when compared with ultra 
high performance liquid chromatography (UHPLC). The order of elution was reversed based 
on hydroxyl- group number, however elution order did not differ between isomeric changes 
in hydroxyl- group position or epimers. Although UPSFC yielded superior resolution and 
selectivity over previously developed UHPLC-MS/MS methods, improvements in sensitivity 
could not be achieved owing to the lower injection volume required for UPSFC relative to 
UHPLC. Method validation was performed on the developed UPSFC-MS/MS method and 
found to be within acceptable limits. Applying the method to the analysis of human serum 
samples showed a significant correlation with serum concentrations of metabolites measured 
by UHPLC-MS/MS (25OHD3 r=0.997, P=<0.001, and 3-epi-25OHD3 r =0.996, P=<0.001). 
These data indicate that UPSFC provides an efficient analytical platform for rapid analysis of 
multiple vitamin D metabolites from serum. 
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1. Introduction 
Vitamin D plays a vital role in calcium homeostasis and bone health, but it has also been 
reported to have extra-skeletal actions, including roles in muscle function, immunity, 
pregnancy and cardiovascular disease [1-4]. Studies of these new facets of vitamin D in 
human health have dramatically increased the demand for analysis of vitamin D ‘status’ for 
research and clinical laboratories. This, in turn, has prompted new strategies for improved 
analysis of vitamin D in biological tissues [5-7]. In particular, there is now increasing interest 
in the measurement of multiple vitamin D metabolites to better define optimal vitamin D 
levels for individual patients. 
 
In humans, vitamin D is derived primarily from photolytic conversion of 7-
dehydrocholesterol to vitamin D3 in the skin [8]. Another form of vitamin D, vitamin D2, is 
derived from dietary sources [9]. Endocrine metabolism of vitamin D involves an initial 
hydroxylation step in the liver to form 25-hydroxyvitamin D (25OHD), which is then further 
hydroxylated to the active form of vitamin D; 1α,25-dihydroxyvitamin D (1α,25(OH)2D). 
This step occurs primarily in the kidneys but can also occur at extra-renal sites [10]. The 
precursors of 1α,25(OH)2D are thought to be inactive, storage and transported forms of 
vitamin D, whilst 1α,25(OH)2D generates a biological response through nuclear receptor 
binding in target tissues [11-14]. Other metabolites produced from 25OHD include 
24R,25(OH)2D3 which is thought to be inactive. Epimerisation of 25OHD2 and 25OHD3 
occurs to form C3-epimers, 3-epi-25OHD [5, 15]. The physiological role of the C3-epimer 
metabolites is not well established, however it does not have the biological activity of 
25OHD converted to 1α,25(OH)2D [5, 16, 17]. 
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All vitamin D metabolites share a cyclopentanoperhydrophenanthrene ring structure [11]. 
The physiological function of 1α,25(OH)2D is determined by the number and position of 
hydroxyl groups. Owing to the structural similarities between metabolites, one of the key 
challenges in the quantitation of multiple vitamin D analytes by mass spectrometry is the 
ability to separate and gain good resolution by chromatographic methods. Liquid 
chromatography-tandem mass spectrometry (UHPLC-MS/MS) methods have achieved the 
necessary resolution for accurate analysis of multiple vitamin D analytes, including 
separating 25OHD from 3-epi-25OHD and 1α,25(OH)2D3 from 24,25(OH)2D3 [6, 18, 19]. 
Whilst UHPLC-MS/MS can provide the necessary resolution and sensitivity for analytical 
methods, this platform does not achieve the resolution power of gas chromatography mass 
spectrometry (GC-MS), however the sensitivity achieved by GC-MS is generally not as high 
as UHPLC-MS/MS to provide lower levels of measurements. Supercritical fluid 
chromatography (SFC) is an alternative separation technique to liquid and gas 
chromatography which applies the use of supercritical fluid in the mobile phase, which can 
improve the resolution of analytical methods as supercritical fluids have diffusivity properties 
of a gas whilst maintaining a low viscosity [20, 21]. The application of SFC with a tandem 
mass spectrometer therefore has the potential to combine the resolving power of gas 
chromatography whilst maintaining low detection limits. The Waters Ultra-Performance 
Convergence Chromatography
TM
 (UPC
2
) system is an application of SFC which uses 
supercritical CO2 with a co-solvent as mobile phases [20]. We have previously shown that 
UPSFC-MS/MS yields improved resolution of multiple steroid metabolites when compared 
to UHPLC-MS/MS [20]. Although, the separation of vitamin D metabolites using SFC has 
previously been described using a SFC-TOF/MS system, to the best of our knowledge no 
UPSFC-MS/MS methods for the analysis of multiple vitamin D metabolites been developed 
and applied to date. It is anticipated that detection limits could be enhanced using SFC-
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MS/MS compared with SFC-TOF/MS [9]. The aim of this study was therefore to develop a 
UPSFC-MS/MS method to measure multiple vitamin D metabolites and to compare the 
resolving power, run time and sensitivity of the resulting method to that of a previously 
established UHPLC-MS/MS method [6]. 
 
2. Materials and methods 
2.1 Materials 
Vitamin D analytical reference standards (vitamin D3, vitamin D2, 25OHD3, 25OHD2, 3-
epi-25OHD3, 1α,25(OH)2D3, 24R,25(OH)2D3 and 23R,25(OH)2D3), deuterated internal 
standards (25OHD3-d3, 3-epi-25OHD3-d3 and 1α,25(OH)2D3-d3) and 4-phenyl-1,2,4-
triazoline-3,5-dione were purchased from Sigma Aldrich (Pool, UK). Lux cellulose-3 chiral 
columns (100 mm, 2 mm, 3 µm) and (150 mm, 3 mm, 3 µm) were purchased from 
Phenomenex (Macclesfield, UK). Waters UPC
2
 BEH column (100 mm, 3 mm, 1.7 µm), 
UPC
2
 fluoro phenyl column (150 mm, 2.1 mm, 1.7 µm) and a 2 µm in line filter were 
purchased from Waters Corporation (Manchester, UK).  Food grade CO2 was purchased from 
BOC, UK and LC-MS grade methanol and formic acid was purchased from Greyhound 
Chromatography (Merseyside, UK). 
 
Sample preparation 
Vitamin D standards were purchased as stock solutions in ethanol. Working solutions were 
prepared in methanol at µg/mL concentration ranges (1-5 µg/mL) for preparation of standard 
curve concentrations and quality controls. Stock solutions were stored at -80 
o
C and working 
standards at -20 
o
C in amber salinized vials. 
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Serum samples were extracted as previously described using supportive liquid-liquid 
extraction (SLE) [6], with slight modification of using 125 µL methanol as reconstitution 
solvent. A derivatization reaction was performed using PTAD and was based on reactions 
previously described [22-25]. Following the SLE elution, 200 µL 0.5 mg/mL PTAD in 
acetonitrile was added to each sample and the reaction occurred at ambient temperature for 2 
hours. The reaction was quenched by the addition of 20 µL water and vortexed before drying 
down with nitrogen and reconstituting with 125 µL methanol for analysis. 
 
2.2 UPSFC-MS/MS 
A Waters ACQUITY UPC
2
 coupled to a Waters Xevo TQ-MS mass spectrometer (Waters 
Corporation, Milford, USA) was used for analysis. A Lux cellulose-3 chiral column (150 
mm, 3 mm, 3 µm) with an ACQUITY UPLC HSS PFP VanGuard Pre-column (1.8 µm, 2.1 
mm x 5 mm) and UPC
2
 BEH column (100 mm, 3 mm, 1.7 µm) were used to separate 
underivatized and derivatized vitamin D metabolites respectively. The mobile phase was CO2 
and 0.1% FA in methanol with a make-up solvent of 0.1% FA, the gradient is described in 
Table 1. The back pressure was set by the automated back pressure regulator (ABPR) set at 
1750 PSI. The column temperature and flow rate were set at 20 
o
C and 1.6 mL/min, 
respectively, for both methods. 
 
Multiple reaction monitoring (MRM) mode was used for quantifying vitamin D metabolites 
using positive electrospray ionisation mode (ESI +). Capillary voltage was set to 3.8 kV and 
desolvation gas flow to 1000 L h
-1
. The source temperature and desolvation temperature were 
set at 120 
o
C and 400
 o
C respectively when measuring underivatized analytes, and 150 
o
C and 
500 
o
C when measuring derivatized 1α,25(OH)2D3. The MRM transitions, cone voltage and 
collision energies for each analyte are displayed in Table 2. An inlet flow rate of 0.1 mL/min 
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was applied to a make-up pump for the flow of 0.1% formic acid prior to the mass 
spectrometer. Data analysis was performed using MassLynx V4.1. 
2.3 Method validation 
The optimised UPSFC-MS/MS method was subjected to method validation which was 
performed based on US Food and Drug Administration (FDA) guidelines [26]. The method 
parameters assessed where accuracy, precision, lower limit of quantitation (LLOQ), lower 
limit of detection (LLOD), linearity and selectivity. Vitamin D depleted charcoal stripped 
serum (Golden West Biologicals Inc.), certified for vitamin D UHPLC-MS/MS applications 
was used as a negative control matrix for validation experiments. Reference concentrations of 
vitamin D standards and internal standards were added to the negative control matrix to 
prepare calibration series and quality control (QC) standards. 
 
The analysis of 41 routine serum samples was performed using the optimised UPSFC-
MS/MS method and using a UHPLC-MS/MS method which has previously been developed 
for the analysis of vitamin D metabolites [6] to inform of the standardisation of 
measurements between platforms. Serum samples for this analysis were collected as 
described previously [6]. 
 
2.4 Data analysis 
Data analysis was performed on Waters MassLynx software. SPSS statistics software was 
used for regression analysis and Bland-Altman plots for comparing measured concentrations 
in serum between methods. 
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3. Results 
3.1 Optimisation of UPSFC conditions 
Full description of optimisation of the UPSFC-MS/MS method is described in the 
supplemental material. The optimised method achieved separation and quantified 9 vitamin 
D metabolites and three deuterated internal standards. Optimal separation was achieved using 
a Lux Cellulose-2 chiral column (150 x 3mm, 3µm) at a flow rate of 1.6 mL/min, heated at 
20 
o
C, which enabled an injection volume of 7 µL. Other optimised method parameters were 
make-up rate of 0.1 mL/min and ABPR set at 1750 psi. The run time of the method was 6 
minutes.  
 
An overall observation of this method compared with UHPLC-MS/MS was that the elution 
order of the UPSFC-MS/MS methods was reversed based on hydroxyl group number. 
UHPLC has previously separated metabolites based primarily on polarity [6]. The elution 
order observed by UHPSFC-MS/MS could be explained by hydrogen bonding and dipole-
dipole interactions [17]. Under UPSFC conditions the stationary phase can act as acceptor of 
hydrogen bonds with the hydroxyl groups from vitamin D analytes. Hence, vitamin D 
analytes with greater number of hydroxyl are retained on column for longer. However, the 
order of elution between sub-groups of metabolites 25OHD3 and 3-epi-25OHD3, along with 
24OHD2 and 25OHD2 was the same on both UPSFC and UHPLC platforms. Comparison of 
chiral column elution order between UPSFC and UHPLC is illustrated on Figure 1. 
Chromatograms of UHPLC and UPSFC-MS/MS methods are shown in Figure 2. 
 
An optimised derivatization method for more sensitive quantitation of 1α,25(OH)2D3 was 
achieved using a UPC
2
 BEH column (100 mm, 3 mm, 1.7 µm) with a flow rate of 1.6 
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mL/min, heated at 20 
o
C. The make-up flow rate and ABPR were optimised at 0.1 mL/min 
and 1750 psi, respectively. 
 
3.2 Optimisation of Mass spectrometry conditions 
The UPSFC mobile phase was combined with make-up solvent from the make-up pump prior 
to ionisation. Optimal ionisation was achieved using make-up solvent of methanol with 0.1% 
FA at a flow rate of 0.1 mL/min. MRM transitions were determined by combined infusion 
into the MS using UHPLC-MS/MS. MRM transitions for PTAD derivatized analytes were 
determined by running full and daughter scans using UPSFC-MS/MS, followed by 
determining optimised cone voltage and collision energies by individual sample injections. 
The abundant ions using 400 
o
C desolvation temperature and 120 
o
C source temperature were 
[M+H]
+
, apart from 24OHD2 and 1α,25(OH)2D3 which were [M-H2O+H]
+
. PTAD 
derivatized abundant ions were [M-H2O+H]
+
 when the desolvation temperatures was 
increased to 500 
o
C. 
 
3.3 Validation 
Accuracy, precision and matrix effects are displayed in Table 3. The accuracy and precision 
values were within the 15% acceptable range of variability for medium and high 
concentration ranges and were within 20% variation at the low concentration. Analysis of 
matrix effects revealed little ion suppression or enhancement by UPSFC-MS/MS analysis. 
Ion suppression ranged from 0.9-5.8%, while ion enhancement was only observed in a low 
and high concentration sample of 3-epi-25OHD3, which was 2.5 and 9.8% respectively.  
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3.4 UPSFC Separation 
The novel UPSFC-MS/MS method achieved the required separation to accurately quantify 
the vitamin D metabolites. Compounds of equal mass were resolved at baseline. The 
resolution factors obtained for pairs of analytes with equal mass are displayed in 
Supplemental Table 2. UPSFC achieved superior resolution factors for analytes of equal 
mass, apart from separation between 25OHD3 and 3-epi-25OHD3 which had a greater 
resolution on UHPLC. Nonetheless, resolution on both platforms between these analytes was 
above the recommended value of 2. It had not previously been possible to achieve baseline 
separation (resolution factor 0.95) between 25OHD2 and 24OHD2 when developing 
UHPLC-MS/MS methods manually or using automated method development software [6, 27] 
(figure 2b). However, baseline separation of 25OHD2 and 24OHD2 (resolution factor 2.5) 
was achieved using the UPSFC with a Lux-Cellulose 2 chiral column (Figure 2a). 
 
Comparison of elution order of vitamin D analytes on a Lux Cellulose chiral column between 
UPSFC and UHPLC revealed a reversal in elution. This was based on hydrogen bonding of 
the hydroxyl groups with the stationary phase using UPSFC, whereas elution order was based 
on polarity with UHPLC (Figure 1). The increase methanol mobile phase in UHPLC eluted 
dihydroxy metabolites followed by single hydroxyl metabolites and vitamin D analogues. 
However, this was reversed on UPSFC, the vitamin D analogues initially eluted, followed by 
single hydroxyl metabolites and dihydroxy metabolites with increased methanol mobile 
phase. The elution order between isomers, 25OHD3 and 3-epi-25OHD3; 24OHD2 and 
25OHD2, was the same on both platforms, although there was a difference in resolving 
power between isomers. 
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3.5 Performance of UPSFC-MS/MS and comparison with UHPLC-MS/MS 
Analysis of 41 routine human serum samples was performed on both UPSFC-MS/MS and 
UHPLC-MS/MS to assess the standardisation between methods and determine potential 
method bias with either separation method. Regression analysis and deviation between 
methods for 25OHD3 and 3-epi-25OHD3 and 25OHD2 measurements is displayed in Figure 
3. Comparison of methods for 25OHD3 (r =0.997, P=<0.001) and 3-epi-25OHD3 (r =0.996, 
P=<0.001) showed a significant correlation between measurements. Measured values of 
25OHD3 between methods gave a mean difference of 1.41% (95% CI 3.576 - -6.410) bias 
towards the measurements by UPSFC-MS/MS, however this was not significant (t =1.907, P 
=0.064). There was a mean bias of 0.61% (95% CI 6.087 - -4.876) towards the UHPLC-
MS/MS measurements of 3-epi-25OHD3 which was found to not be significant (t =1.065, 
P=0.293). Previous reported concentrations of 1α,25(OH)2D3 range between 20-120 pg/mL 
[5]. The LLOQ of 1α,25(OH)2D3 for this method when derivatized with PTAD was 80 
pg/mL, hence the routine serums run as part of this method could not be quantified. It is 
anticipated that with future work applying this method on a later generation mass 
spectrometer would achieve the required detection limits to routinely quantify in serum. 
 
4. Discussion and conclusions 
Development of a novel UPSFC-MS/MS method described above has enabled the 
comparison of established UHPLC-MS/MS method for quantifying multiple vitamin D 
metabolites. The optimised UPSFC method achieved the required separation over a 6 minute 
run time, separating chiral metabolites 23,25(OH)2D3, 24,25(OH)2D3 and 1α,25(OH)2D3 
along with the C3-epimer 3-epi-25OHD3 from 25OHD2 and 24OHD2 from 25OHD2. 
Separation achieved by UPSFC was overall superior compared to UHPLC, whilst reducing 
the run time to 6 minutes compared with 8 minutes required for UHPLC separation. This 
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method demonstrated the ability of UPSFC-MS/MS to resolve and quantify structurally 
similar metabolites, specifically where the position or bond direction of a hydroxyl group is 
the only structural difference, utilizing hydrogen bonding of the analytes with the stationary 
phase. This improved resolution has also been shown previously for other endocrine 
androgen metabolites [20]. 
 
Previous methods for vitamin D using UHPLC have enabled injection volumes of 20 µL 
whilst maintaining symmetrical peak shape. A limitation whilst developing this method was 
maximum injection volume which was limited dependant on column length and width. A 
maximum injection volume of 7 µL could be achieved with high injection volumes above 7 
µL resulting in peak saturation Supplemental Figure 4. As less analyte could be injected 
onto the column on the UPSFC-MS/MS, the achieved limits of quantitation were less than 
observed for the UHPLC-MS/MS when compared on the same Waters Xevo TQ-MS mass 
spectrometer. Owing to the low endogenous levels of some metabolites in the vitamin D 
pathway it was not possible to quantify the metabolites 1α,25(OH)2D3, 23,25(OH)2D3 or 
24OHD2 under current conditions. To achieve the required sensitivity necessary for routine 
serum analysis of these analytes by UPSFC, analysis in tandem with a later generation mass 
spectrometer is required. However, the reduced injection volume enables additional repeat 
injections from the same samples, to allow monitoring of sample reproducibility.  
 
The UPSFC-MS/MS method described was developed as an alternative approach to UHPLC-
MS/MS methods for measuring multiple metabolites of vitamin D in clinical applications to 
determine changes in vitamin D metabolism. The use of UPSFC has clear advantages over 
LC for routine analysis including higher throughput and improved separation for accurate 
quantitation. Matrix effects analysis ensured no signal interferences altering measured values. 
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The use of supercritical CO2 is also advantageous owing to reduced costs and environmental 
effects compared with organic solvents used for reversed phase LC [20, 28]. This approach to 
analysis would be beneficial in a number of method development facilities which involve 
high throughput analysis separating structurally similar metabolites. However, measuring 
analytes at low concentration levels (pg/mL) will likely require latest generation mass 
spectrometry platforms or structural modifications to improve ionisation such as 
derivatization owing reduced sample injection volumes for UPSFC application columns. 
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Figure 1: Elution order depicted between UPSFC and UHPLC. 
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Figure 2: Chromatographic separation of vitamin D metabolites by UPSFC-MS/MS and 
UHPLC-MS/MS. 
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Figure 3: Regression analysis of the UPSFC-MS/MS and UHPLC-MS/MS methods for 
25OHD3 and 3-epi-25OHD3 concentrations analysed with a cohort of serum samples (n=41). 
The regression line and 95% confidence intervals are represented. Bland Altman plots for the 
comparison of UHPLC-MS/MS and UPSFC-MS/MS for analysis of 25OHD3 and 3-epi-
25OHD3, showing the mean bias (solid line) and ±SD (dotted lines). 
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Table 1 – Mobile phase gradients for two analytical methods. 
Underivatized vitamin D Mobile phase A Mobile phase B 
Run time (minutes) CO2 (%) Methanol (%) 
0 95.0 5.0 
2.8 - 3.0 73.0 27.0 
4.5 - 6.5 95.0 5.0 
Derivatized 1α,25(OH)2D3   
Run time (minutes) CO2 (%) Methanol (%) 
0 95.0 5.0 
2.0 - 2.2 60.0 40.0 
2.7 - 3.5 95.0 5.0 
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Table 2 - MRM transitions of vitamin D metabolites, mass spectrometry parameters and retention time. 
Abbrev. Name 
Mass 
transitions 
Cone 
voltage 
Collision 
energy 
Retention 
Time (min) 
UPSFC-MS/MS 
Retention 
Time (min) 
UHPLC-MS/MS 
25OHD3 25-Hydroxyvitamin D3 
401.4 > 135.1 
401.4 > 151.1 
18 
18 
22 
12 
2.06 3.47 
25OHD2 25-Hydroxyvitamin D2 
413.4 > 105.0 
413.4 > 353.3 
16 
16 
40 
8 
2.38 3.68 
24OHD2 24-Hydroxyvitamin D2 
395.3 > 119.1 
395.3 > 269.1 
26 
26 
26 
22 
2.18 3.57 
3-Epi-25OHD3 3-Epi-25-hydroxyvitamin D3 
401.4 > 159.1 
401.4 > 365.3 
18 
18 
26 
10 
2.24 4.10 
1α,25(OH)2D3 1α,25-Dihydroxyvitamin D3 
399.3 > 135.1 
399.3 > 151.1 
24 
24 
18 
24 
2.64 2.43 
24R,25(OH) 2D3 24,25-Dihydroxyvitamin D3 
417.4 > 121.1 
417.4 > 381.3 
16 
16 
18 
10 
2.48 2.57 
23R,25(OH) 2D3 23,25-Dihydroxyvitamin D3 
417.3 > 325.2 
417.3 > 121.1 
16 
16 
10 
24 
2.21 3.01 
Vitamin D2 Vitamin D2 397.3 > 69.0 20 22 1.33 5.02 
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397.3 > 104.5 20 32 
Vitamin D3 Vitamin D3 
385.3 > 105.0 
385.3 > 259.2 
20 
20 
40 
14 
5.02 4.84 
25OHD3-d3 25-Hydroxyvitamin D3-d3 
404.4 > 135.1 
404.4 > 151.1 
16 
16 
12 
16 
2.06 3.47 
3-Epi-25OHD3-d3 3-Epi-25-hydroxyvitamin D3-d3 
404.4 > 159.1 
404.4 > 365.3 
16 
16 
22 
10 
2.24 4.10 
1α,25(OH)2-d3 1α,25-Dihydroxyvitamin D3-d3 
402.3 > 135.1 
402.3 > 151.1 
20 
20 
18 
20 
2.64 2.43 
Vitamin D2-d3 Vitamin D2-d3 
400.3 > 69.0 
400.3 > 104.5 
20 
20 
32 
16 
1.33 5.02 
       
1α,25(OH)2D3-PTAD 
1α,25-Dihydroxyvitamin D3-4- Phenyl-
1,2,4-triazoline-3,5-dione 
574.3 > 314.1 
574.3 > 298.2 
22 
22 
16 
16 
1.87 3.95 
24R,25(OH)2D3-PTAD 
24,25-Dihydroxyvitamin D3- Phenyl-
1,2,4-triazoline-3,5-dione 
574.3> 298.2 
574.3> 279.9 
22 
20 
18 
28 
2.00 3.76 
1α,25(OH)2D3-d3-
PTAD 
1α,25-Dihydroxyvitamin D3-4- Phenyl-
1,2,4-triazoline-3,5-dione 
577.3> 317.1 
577.3> 301.2 
16 
20 
15 
16 
1.87 3.95 
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Table 3 - Method validation data. 
Compound 
 
Conc. 
(ng/mL) 
Level 
 Precision (%) RSD Accuracy 
(%) 
 
Matrix effect % 
 Intra-day 
N=6 
Inter-day 
N=18 
N=6  
Conc 
(ng/mL) 
N=3 
25OHD3 
5.0 Low  8.78 15.9 99.5  5.0 -1.0 
20.0 Medium  5.28 7.5 87.2  25.0 -2.8 
100.0 High  4.05 4.2 99.0  100.0 -2.3 
  
  
 
  
    
3-Epi-25OHD3 
1.00 Low  11.8 9.8 99.1  5.0 2.5 
5.00 Medium  8.3 6.8 98.4  25.0 -5.8 
25.00 High  6.2 4.0 91.6  100.0 9.8 
  
  
 
  
    
1α,25(OH)
2
D3-
PTAD 
0.70 Low  6.0 7.6 93.5  0.50 -0.5 
1.40 Medium  2.5 4.6 97.8  2.50 -3.0 
3.00 High  2.7 4.7 100.3  8.0 -1.1 
  
  
 
  
    
24R,25(OH)
2
D3 
0.70 Low  3.9 9.4 92.5  2.0 -1.0 
1.40 Medium  6.8 13.0 95.8  3.0 -0.9 
3.00 High  5.5 10.6 100.9  7.0 -1.0 
  
  
 
  
    
25OHD2 
1.00 Low  8.7 10.3 123.2    
5.00 Medium  10.0 13.2 104.3  10.0 -1.5 
25.0 High  9.1 11.5 97.4  100.0 -3.8 
          
 0.80 Low  7.7 6.9 102.1  1.0 -2.1 
24OHD2 4.00 Medium  8.0 9.2 101.9  5.0 -2.4 
 20.00 High  8.2 8.4 103.9  50.0 -3.2 
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Highlights 
 High throughput UPSFC-MS/MS to measure multiple vitamin D metabolites. 
 Order of elution was reversed compared with LC-MS/MS based on hydroxyl group number. 
 Chiral column separation enabled separation of analytes on UPSFC. 
 Analysis of serum samples shows correlation between UPSFC-MS/MS and LC-MS/MS for 
routine serum measurements for 25OHD3 measurements. 
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